Literatur
- 1
Ahmed A, Turner G, King B. et
al .
Midgut neuroendocrine tumours with liver metastases:.
Endocr Relat Cancer.
2009;
16
885-894
- 2
Arnold R, Trautmann M E, Creutzfeldt W. et al .
Somatostatin analogue octreotide and inhibition
of tumour growth in metastatic endocrine gastroenteropancreatic
tumours.
Gut.
1996;
38
430-438
- 3
Bahra M, Jacob D, Pascher A. et
al .
Surgical strategies and predictors of outcome for
malignant neuroendocrine tumors of the pancreas.
J Gastroenterol
Hepatol.
2007;
22
930-935
- 4
Ben-Shlomo A, Melmed S.
Drug profile: Pasireotide – a
somatostatin analog for the potential treatment of acromegaly, neuroendocrine
tumors and Cushing’s disease.
IDrugs.
2007;
10
885-895
- 5
Berber E, Flesher N, Siperstein A E.
Laparoscopic radiofrequency ablation of neuroendocrine liver
metastases.
World J Surg.
2002;
26
985-990
- 6
Bushnell D L, O’Dorisio T M, O’Dorisio M S. et al .
90Y-Edotreotide
for metastatic carcinoid refractory to octreotide.
J Clin
Oncol.
2010;
28
1652-1659
- 7
Doerffel Y, Wermke W.
Neuroendocrine tumors:
characterization with contrast-enhanced ultrasonography.
Ultraschall
Med.
2008;
29
506-514
- 8
Ekeblad S, Sundin A, Janson E T. et al .
Temozolomide as monotherapy is effective
in treatment of advanced malignant neuroendocrine tumors.
Clin Cancer
Res.
2007;
13
2986-2991
- 9
Eriksson J, Stalberg P, Nilsson A. et al .
Surgery and radiofrequency ablation for
treatment of liver metastases from midgut and foregut carcinoids
and endocrine pancreatic tumors.
World J Surg.
2008;
32
930-938
- 10
Ezziddin S, Logvinski T, Yong-Hing C. et al .
Factors predicting tracer uptake in somatostatin
receptor and MIBG scintigraphy of metastatic gastroenteropancreatic
neuroendocrine tumors.
J Nucl Med.
2006;
47
223-233
- 11
Ezziddin S, Opitz M, Attassi M. et al .
Impact of the Ki-67 proliferation index on
response to peptide receptor radionuclide therapy.
Eur
J Nucl Med Mol Imaging.
2011;
38
459-466
- 12
Faiss S, Pape U F, Böhmig M. et al .
Prospective, randomized, multicenter trial
on the antiproliferative effect of lanreotide, interferon-alfa,
and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic
tumors.
J Clin Oncol.
2003;
21
2689-2696
- 13
Faivre S, Debaldo C, Vera K. et al .
Safety, pharmacokinetic, and antitumor activity
of SU11248, a novel oral multitarget tyrosine kinase inhibitor,
in patients with cancer.
J Clin Oncol.
2006;
24
25-35
- 14
Givi B, Pommier S EJ, Thompson A K. et al .
Operative resection of primary carcinoid
neoplasms in patients with liver metastases yields significantly better
survival.
Surgery.
2006;
140
891-898
- 15
Hanahan D, Weinberg R A.
Hallmarks
of cancer: the next generation.
Cell.
2011;
144
646-674
- 16
Hellman P, Ladjevardi S, Skogseid B. et al .
Radiofrequency tissue ablation using cooled
tip for liver metastases of neuroendocrine tumors.
orld
J Surg.
2002;
26
1052-1056
- 17
Jann H, Roll S, Couvelard A. et
al .
Neuroendocrine tumors of midgut and hindgut origin:
tumor-node-metastasis classification determines clinical outcome.
Cancer.
2011;
117
3332-3341
- 18
King J, Quinn R, Glenn D M. et al .
Radioembolization with selective internal radiation
microspheres for neuroendocrine liver metastases.
Cancer.
2008;
113
921-929
- 19 Klimstra D S. et al .In: Bosman FT, Carneiro
F, Hruban RH, Theise ND WHO Classification of Tumours of
the Digestive System. Lyon; IARC 2010
- 20
Kulke M H, Hornick J L, Frauenhoffer C. et al .
O6-methylguanine DNA methyltransferase
deficiency and response to temozolomide-based therapy in patients
with neuroendocrine tumors.
Clin Cancer Res.
2009;
15
338-345
- 21
Kulke M H, Lenz H J, Meropol N J. et al .
Activity of Sunitinib in
patients with advanced neuroendocrine tumors.
J Clin Oncol.
2008;
26
3403-3410
- 22
Kwekkeboom D J, deHerder W W, Kam B L. et al .
Treatment with the radiolabeled
somatostatin analog [177Lu-DOTA0,Tyr3]octreotate:
toxicity, efficacy, and survival.
J Clin Oncol.
2008;
26
2124-2130
- 23
Marrache F, Vuillerme M P, Roy C. et al .
Arterial phase enhancement and body mass
index are predictors of response to chemoembolisation for liver
metastases of endocrine tumours.
Br J Cancer.
2007;
96
49-55
- 24
Moertel C G, Kvols L K, O’Connel M J. et al .
Treatment of neuroendocrine
carcinomas with combined etoposide and cisplatin.
Cancer.
1991;
68
227-232
- 25
Moertel C G, Lefkopoulo M, Lipsitz S. et al .
Streptozotocin-doxorubicin, streptozotocin-fluorouracil
or chlorozotocin in the treatment of advanced islet cell carcinoma.
N Engl J Med.
1992;
326
519-523
- 26
Niederle M B, Hackl M, Kaserer K. et al .
Gastroenteropancreatic neuroendocrine tumours:
the current incidence and staging based on the WHO and European
Neuroendocrine Tumour Society classification.
Endocr Relat Cancer.
2010;
17
909-918
- 27
Otte A, Mueller-Brand J, Dellas S. et al .
Yttrium-90-labelled somatostatin-analogue
for cancer treatment.
Lancet.
1998;
351
417-418
- 28
Pape U F, Berndt U, Müller-Nordhorn J. et al .
Prognostic factors of long-term outcome
in gastroenteropancreatic neuroendocrine tumours.
Endocr
Relat Cancer.
2008;
15
1083-1097
- 29
Pape U F, Böhmig M, Berndt U. et al .
Survival and clinical outcome of patients
with neuroendocrine tumors of the gastroenteropancreatic tract in a
German referral center.
Ann NY Acad Sci.
2004;
1014
222-233
- 30
Pape U F, Jann H, Müller-Nordhorn J. et al .
Prognostic relevance of
a novel TNM classification system for upper gastroenteropancreatic
neuroendocrine tumors.
Cancer.
2008;
113
256-265
- 31
Pascher A, Steinmüller T, Radke C. et al .
Primary and secondary hepatic manifestation
of neuroendocrine tumors.
Langenbeck’s Arch Surg.
2000;
385
265-270
- 32
Pavel M E, Baum U, Hahn E G. et al .
Doxorubicin and streptozotocin after failed
biotherapy of neuroendocrine tumors.
Int J Gastrointest
Cancer.
2005;
35
179-186
- 33
Pavel M E, Baum U, Hahn E G. et al .
Efficacy and tolerability of Pegylated IFN-α in
patients with neuroendocrine gastroenteropancreatic carcinomas.
J Interferone Cytokine Res.
2006;
26
8-13
- 34
Pietras K, Hanahan D.
A Multitargeted, metronomic,
and maximum-tolerated dose ‘‘chemo-switch’’ regimen
is antiangiogenic, producing objective responses and survival benefit
in a mouse model of cancer.
J Clin Oncol.
2005;
23
939-952
- 35
Plöckinger U, de Herder W W, Wiedenmann B (Hrsg).
Consensus guidelines for
the standard of care for patients with digestive neuroendocrine
tumors.
Neuroendocrinology.
2009;
90
159-234
- 36
Plöckinger U, Kloeppel G, Wiedenmann B. et al .
The German NET-registry: an audit on the
diagnosis and therapy of neuroendocrine tumors.
Neuroendocrinology.
2009;
90
349-363
- 37
Raymond E, Dahan L, Raoul J L. et al .
Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors.
N Engl J Med.
2011;
364
501-513
- 38
Rindi G, Klöppel G, Ahlmann H. et al .
TNM staging of foregut (neuro)endocrine
tumors: A consensus proposal including a grading system.
Virchows
Arch.
2006;
449
395-401
- 39
Rindi G, Klöppel G, Couvelard A. et al .
TNM staging of midgut and hindgut (neuro)endocrine
tumors: a consensus proposal including a grading system.
Virchows
Arch.
2007;
451
757-762
- 40
Rinke A, Müller H H, Schade-Brittinger C. et al .
Placebo-controlled, double-blind,
prospective, randomized study on the effect of octreotide LAR in the
control of tumor growth in patients with metastatic neuroendocrine midgut
tumors: a report from the PROMID Study Group.
J Clin Oncol.
2009;
27
4656-4663
- 41
Ruf J, Schiefer J, Furth C. et
al .
68Ga-DOTATOC PET/CT of Neuroendocrine Tumors:
Spotlight on the CT Phases of a Triple-Phase Protocol.
J
Nucl Med.
2011;
52
697-704
- 42
Ruutiainen A T, Soulen M C, Tuite C M. et al .
Chemoembolization and bland embolization
of neuroendocrine tumor metastases to the liver.
J Vasc
Interv Radiol.
2007;
18
847-855
- 43 Sobin L H, Gospodarowicz M K, Wittekind C. TNM classification of malignant
tumours. Wiley & Blackwell. Oxford; 2009
- 44
Strosberg J R, Fine R L, Choi J. et al .
First-line chemotherapy with capecitabine
and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Cancer.
2011;
117
268-275
- 45
Wolin E M, Kvols L, Ezzat S. et
al .
Pasireotide LAR in patients with metastatic carcinoid
tumors: pharmacokinetics (PK) and safety results from a randomized,
multicenter, phase I study.
Abstract Proc ASCO.
2009;
- 46
Yao J C, Hassan M, Phan A. et
al .
One hundred years after „carcinoid”:
epidemiology of and prognostic factors for neuroendocrine tumors
in 35,825 cases in the United States.
J Clin Oncol.
2008;
26
3063-3072
- 47
Yao J C, Lombard-Bohas C, Baudin E. et al .
Daily oral everolimus activity in patients
with metastatic pancreatic neuroendocrine tumors after failure of
cytotoxic chemotherapy.
J Clin Oncol.
2010;
28
69-71
- 48
Yao J C, Phan A, Hoff P M. et al .
Targeting vascular endothelial growth factor in
advanced carcinoid tumor: a random assignment phase II study of
depot octreotide with bevacizumab and pegylated interferon alfa-2b.
J Clin Oncol.
2008;
26
1316-1323
- 49
Yao J C, Shah M H, Ito T. et al .
Everolimus for advanced pancreatic neuroendocrine
tumors.
N Engl J Med.
2011;
364
514-523
- 50
Zitzmann K, De Toni E M, Brand S. et al .
The novel mTOR inhibitor RAD001 (everolimus)
induces antiproliferative effects in human pancreatic neuroendocrine
tumor cells.
Neuroendocrinology.
2007;
85
54-60
1
Widmung Herrn
Chefarzt i.R. Dr. med. Joachim Quäck posthum in Hochachtung,
Verehrung und Zuneigung gewidmet.
Dr. med. U.-F. Pape
Medizinische Klinik m. S. Hepatologie und
Gastroenterologie
Charité – Universitätsmedizin
Berlin
Campus Virchow Klinikum
Augustenburger
Platz 1
13353 Berlin
Email: ulrich-frank.pape@charite.de
